Year: 2017
Type: review
Abstract: Residual cardiovascular (CV) risk remains in some patients despite optimized statin therapy and may necessitate add-on therapy to reduce this risk. Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, lowers plasma triglyceride levels without raising low-density lipoprotein cholesterol levels and has potential beneficial effects on atherosclerotic plaques. Animal studies have shown that EPA reduces levels of pro-inflammatory cytokines and chemokines. In clinical trials utilizing a wide spectrum of plaque imaging modalities, EPA has shown beneficial effects on plaque characteristics. Studies of patients with coronary artery disease receiving statin therapy suggest that EPA may decrease plaque vulnerability and prevent plaque progression. EPA also decreased pentraxin-3 and macrophage accumulation. A large, randomized, Japanese study reported that EPA plus a statin resulted in a 19% relative reduction in major coronary events at 5years versus a statin alone in patients with hypercholesterolemia (P=0.011). Icosapent ethyl, a high-purity prescription form of EPA ethyl ester, has been shown to reduce triglyceride levels and markers of atherosclerotic inflammation. Results of an ongoing CV outcomes study will further define the potential clinical benefits of icosapent ethyl in reducing CV risk in high-risk patients receiving statin therapy.
Source: Vascular Pharmacology
Authors: J.R. Nelson, O. Wani, H.T. May, M. Budoff
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Keywords: eicosapentaenoic acid, icosapent ethyl, omega-3 fatty acids, atherosclerotic plaque, residual cardiovascular risk, statin therapy, plaque vulnerability, plaque progression, pentraxin 3, macrophage accumulation, atherosclerotic inflammation, coronary artery disease, hypercholesterolemia, triglyceride lowering
Open Access status: hybrid
Estimated APC paid: $3,670
Funders: Amarin Corporation, Amarin Pharma
OpenAlex ID: W2592571300
